Novo Nordisk says Alzheimer's drug trial fails to meet main goal

Core Viewpoint - Novo Nordisk announced that an older oral version of its semaglutide drug did not achieve its primary objective in late-stage trials aimed at assessing its effectiveness in slowing cognitive decline in Alzheimer's patients [1] Group 1 - The late-stage trials were specifically designed to evaluate the impact of semaglutide on cognitive decline [1] - The failure to meet the main goal raises questions about the drug's efficacy in treating Alzheimer's disease [1] - This outcome may affect Novo Nordisk's strategy and future developments in the Alzheimer's treatment space [1]